Cargando…
Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
BACKGROUND: Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). Vesicle-associated membrane protein 2 (VAMP-2) has emerged as a promising biomarker of AD-related synapse...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612328/ https://www.ncbi.nlm.nih.gov/pubmed/37898760 http://dx.doi.org/10.1186/s13195-023-01336-0 |
_version_ | 1785128679798472704 |
---|---|
author | Goossens, Julie Cervantes González, Alba Dewit, Nele Lidón, Laia Fortea, Juan Alcolea, Daniel Lleó, Alberto Belbin, Olivia Vanmechelen, Eugeen |
author_facet | Goossens, Julie Cervantes González, Alba Dewit, Nele Lidón, Laia Fortea, Juan Alcolea, Daniel Lleó, Alberto Belbin, Olivia Vanmechelen, Eugeen |
author_sort | Goossens, Julie |
collection | PubMed |
description | BACKGROUND: Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). Vesicle-associated membrane protein 2 (VAMP-2) has emerged as a promising biomarker of AD-related synapse degeneration in cerebrospinal fluid (CSF). The aim of this study was to explore the CSF profile of VAMP-2 across the AD continuum in relation to core AD biomarkers, other synaptic proteins, neurogranin (Ng) and synaptosomal-associated Protein-25 kDa (SNAP-25) and cognitive performance. METHODS: We developed a digital immunoassay on the Single Molecule Array platform to quantify VAMP-2 in CSF and used existing immunoassays to quantify Ng, SNAP-25 and core CSF AD biomarkers. The clinical study included 62 cognitively unimpaired AD biomarker-negative subjects and 152 participants across the AD continuum from the SPIN cohort (Sant Pau Initiative on Neurodegeneration). Cognitive measures of episodic, semantic, executive and visuospatial domains and global cognition were included. Statistical methods included χ(2) tests, spearman correlation, and ANCOVA analyses. RESULTS: The VAMP-2 assay had a good analytical performance (repeatability 8.9%, intermediate precision 10.3%). Assay antibodies detected native VAMP-2 protein in human brain homogenates. CSF concentrations of VAMP-2, neurogranin and SNAP-25 were lower in preclinical AD stage 1 compared to controls and higher at later AD stages compared to AD stage 1 and were associated with core AD biomarkers, particularly total tau (adj. r(2) = 0.62 to 0.78, p < 0.001). All three synaptic proteins were associated with all cognitive domains in individuals on the AD continuum (adj. r(2) = 0.04 to 0.19, p < 0.05). CONCLUSIONS: Our novel digital immunoassay accurately measures VAMP-2 changes in CSF, which reflect AD biomarkers and cognitive performance across multiple domains. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01336-0. |
format | Online Article Text |
id | pubmed-10612328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106123282023-10-29 Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum Goossens, Julie Cervantes González, Alba Dewit, Nele Lidón, Laia Fortea, Juan Alcolea, Daniel Lleó, Alberto Belbin, Olivia Vanmechelen, Eugeen Alzheimers Res Ther Research BACKGROUND: Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). Vesicle-associated membrane protein 2 (VAMP-2) has emerged as a promising biomarker of AD-related synapse degeneration in cerebrospinal fluid (CSF). The aim of this study was to explore the CSF profile of VAMP-2 across the AD continuum in relation to core AD biomarkers, other synaptic proteins, neurogranin (Ng) and synaptosomal-associated Protein-25 kDa (SNAP-25) and cognitive performance. METHODS: We developed a digital immunoassay on the Single Molecule Array platform to quantify VAMP-2 in CSF and used existing immunoassays to quantify Ng, SNAP-25 and core CSF AD biomarkers. The clinical study included 62 cognitively unimpaired AD biomarker-negative subjects and 152 participants across the AD continuum from the SPIN cohort (Sant Pau Initiative on Neurodegeneration). Cognitive measures of episodic, semantic, executive and visuospatial domains and global cognition were included. Statistical methods included χ(2) tests, spearman correlation, and ANCOVA analyses. RESULTS: The VAMP-2 assay had a good analytical performance (repeatability 8.9%, intermediate precision 10.3%). Assay antibodies detected native VAMP-2 protein in human brain homogenates. CSF concentrations of VAMP-2, neurogranin and SNAP-25 were lower in preclinical AD stage 1 compared to controls and higher at later AD stages compared to AD stage 1 and were associated with core AD biomarkers, particularly total tau (adj. r(2) = 0.62 to 0.78, p < 0.001). All three synaptic proteins were associated with all cognitive domains in individuals on the AD continuum (adj. r(2) = 0.04 to 0.19, p < 0.05). CONCLUSIONS: Our novel digital immunoassay accurately measures VAMP-2 changes in CSF, which reflect AD biomarkers and cognitive performance across multiple domains. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01336-0. BioMed Central 2023-10-28 /pmc/articles/PMC10612328/ /pubmed/37898760 http://dx.doi.org/10.1186/s13195-023-01336-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Goossens, Julie Cervantes González, Alba Dewit, Nele Lidón, Laia Fortea, Juan Alcolea, Daniel Lleó, Alberto Belbin, Olivia Vanmechelen, Eugeen Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum |
title | Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum |
title_full | Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum |
title_fullStr | Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum |
title_full_unstemmed | Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum |
title_short | Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum |
title_sort | evaluation of cerebrospinal fluid levels of synaptic vesicle protein, vamp-2, across the sporadic alzheimer’s disease continuum |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612328/ https://www.ncbi.nlm.nih.gov/pubmed/37898760 http://dx.doi.org/10.1186/s13195-023-01336-0 |
work_keys_str_mv | AT goossensjulie evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum AT cervantesgonzalezalba evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum AT dewitnele evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum AT lidonlaia evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum AT forteajuan evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum AT alcoleadaniel evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum AT lleoalberto evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum AT belbinolivia evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum AT vanmecheleneugeen evaluationofcerebrospinalfluidlevelsofsynapticvesicleproteinvamp2acrossthesporadicalzheimersdiseasecontinuum |